CoChat

USP8 Is a Novel Target for Overcoming Gefitinib Resistance in Lung Cancer

Open access
Byun, Sanguine, Lee, Sung-Young, Lee, Jihoon, Jeong, Chul-Ho, Farrand, Lee, Lim, Semi, Reddy, Kanamata, Kim, Ji Young, Lee, Mee-Hyun, Lee, Hyong Joo, Bode, Ann M., Won Lee, Ki, Dong, Zigang · 2013 · Clinical Cancer Research
Cited by 147

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

Purpose: Common treatment modalities for non–small cell lung cancer (NSCLC) involve the EGF receptor-tyrosine kinase inhibitors (EGFR-TKIs) like gefitinib and erlotinib. However, the vast majority of treated patients acquire resistance to EGFR-TKIs, due, in large part, to secondary mutations in EGFR or amplification of the MET gene. Our purpose was to test ubiquitin-specific peptidase 8 (USP8) as a potential therapeutic target for gefitinib-resistant and -sensitive non–small cell lung cancer (NSCLC). Experimental Design: Testing the effect of knockdown of USP8 and use of a synthetic USP8 inhibitor to selectively kill gefitinib-resistant (or -sensitive) NSCLCs with little effect on normal cells in cell culture and a xenograft mouse model. Results: Knockdown of ubiquitin-specific peptidase 8 (USP8) selectively kills gefitinib-resistant NSCLCs while having little toxicity toward normal cells. Genetic silencing of USP8 led to the downregulation of several receptor tyrosine kinases (RTK) including EGFR, ERBB2, ERBB3, and MET. We also determined that a synthetic USP8 inhibitor markedly decreased the viability of gefitinib-resistant and -sensitive NSCLC cells by decreasing RTK expression while having no effect on normal cells. Moreover, treatment with a USP8 inhibitor led to significant reductions in tumor size in a mouse xenograft model using gefitinib-resistant and -sensitive NSCLC cells. Conclusions: Our results show for the first time that the inhibition of USP8 activity or reduction in USP8 expression can selectively kill NSCLC cells. We propose USP8 as a potential therapeutic target for gefitinib-resistant and -sensitive NSCLC cells. Clin Cancer Res; 19(14); 3894–904. ©2013 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-12-3696

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 147

Metadata

Authors
Byun, S., Lee, S.-Y., Lee, J., Jeong, C.-H., Farrand, L., Lim, S., Reddy, K., Kim, J. Y., Lee, M.-H., Lee, H. J., Bode, A. M., Won Lee, K., & Dong, Z.
Venue
Clinical Cancer Research
Published
2013-07-15
Volume
19
Issue
14
Pages
3894-3904
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2097079447
Cited by
147
References
12
FWCI
8.04
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: USP8 Is a Novel Target for Overcoming Gefitinib Resistance in Lung Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-12-3696
The paper
Byun, S., Lee, S.-Y., Lee, J., Jeong, C.-H., Farrand, L., Lim, S., Reddy, K., Kim, J. Y., Lee, M.-H., Lee, H. J., Bode, A. M., Won Lee, K., & Dong, Z. (2013). USP8 Is a Novel Target for Overcoming Gefitinib Resistance in Lung Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-12-3696

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.